Nat Rev Clin Oncol 2011 ;8(11):661-8. [IF:10.787]
Personalized medicine in lung cancer: what we need to know.
Mok TS .
Department of Clinical Oncology, The Chinese University of Hong Kong, State Key Laboratory of South China, Sha Tin, Hong Kong, China. tony@clo.cuhk.edu.hk.
香港中文大学临床肿瘤学系
Abstract
Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes involving ALK has set the stage for personalized medicine for lung cancer. Patients selected using biomarkers have benefited from the development of EGFR tyrosine kinase inhibitors and ALK inhibitors with considerable improvement in tumor control and survival. Four key areas of knowledge that are essential to the development of targeted therapy are discussed in this Review: knowing the target, knowing the biomarker, knowing the end point and knowing the mechanisms of resistance.
版权声明
本网站所有注明“来源：丁香园”的文字、图片和音视频资料，版权均属于丁香园所有，非经授权，任何媒体、网站或个人不得转载，授权转载时须注明“来源：丁香园”。本网所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。同时转载内容不代表本站立场。
更多 >
肺癌相关文章
近期热门文章
